Cancer Treatment Reviews
Volume 24, Issue 1 , Pages 3-14 , February 1998

Locoregional treatments of unresectable liver metastases from colorectal cancer

References 

  1. Silverberg E, Lubana J. Cancer statistics. 1988;38:5–22 CA
  2. Kemeny N. The systemic chemotherapy of hepatic metastases from colorectal cancer. Sem Oncol. 1983;10:148–158
  3. Gilbert HA, Kagan AR. Metastases: incidence, detection and evaluation without histologic confirmation. In:  Weiss L editors. Fundamental Aspects of Metastasis. Amsterdam: North-Holland; 1976;p. 385–405
  4. Ballantyne GH, Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer. 1993;71:4252–4266
  5. Cady B, Stone MD. The role of surgical resection of liver metastases in colorectal carcinoma. Sem Oncol. 1991;18:399–406
  6. Adson MA. Resection of liver metastases: when is it worthwhile?. World J Surg. 1987;11:511–520
  7. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br J Surg. 1990;77:1241–1246
  8. Fong Y, Cohen AM, Fortner JG, et al.  Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938–946
  9. Fuhrman GM, Curley SA, Hohn DC, Roh MS. Improved survival after resection of colorectal liver metastases. Ann Surg Oncol. 1995;2:537–541
  10. Nordlinger B, Guiguet M, J-C Vaillant, et al.  Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996;77:1254–1262
  11. Cady B, Stone M, McDermott WV, et al.  Technical and biological factors in disease-free survival after hepatic resection for colorectal metastases. Arch Surg. 1992;127:1561–1569
  12. Steele G, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol. 1991;9:1105–1112
  13. van Ooijen B, Wiggers T, Meijer S, et al.  Hepatic resections for colorectal metastases in The Netherlands—A multi-institutional 10-year study. Cancer. 1992;70:28–34
  14. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13–29
  15. Vetto JT, Hughes KS, Rosenstein R, Sugarbaker PH. Morbidity and mortality of hepatic resection for metastatic colorectal carcinoma. Dis Colon Rectum. 1990;33:408–413
  16. Petrelli N, Gupta B, Piedmonte M, Herrera L. Morbidity and survival of liver resection for colorectal adenocarcinoma. Dis Colon Rectum. 1991;34:899–904
  17. Ravikumar TS, Steele GD. Hepatic cryosurgery. Liver Surg. 1989;69:433–440
  18. Gage A, Fazekas G, Riley E. Freezing entry to large blood vessels in dogs. Surgery. 1967;615:748–754
  19. Ravikumar JC, Kane R, Cady R, et al.  Hepatic cryosurgery with intraoperative ultrasound monitoring for metastatic colon carcinoma. Arch Surg. 1987;22:403–409
  20. Sheu J, Lee C, Sung J, Chen D, Yang P, Lin T. Intraoperative sonography: An indispensable procedure in resection of small hepatocellular carcinomas. Surgery. 1985;97:97–103
  21. Weaver L, Atkinson D, Zemel R. Hepatic cryosurgery in treating colorectal metastases. Cancer. 1995;76:210–214
  22. Onik G, Rubinsky B, Zemel R, et al.  Ultrasound-guided hepatic cryosurgery in the treatment of metastatic colon carcinoma. Cancer. 1991;67:901–907
  23. Ravikumar TS, Steele GD, Kane R, King V. Experimental and clinical observations on hepatic cryosurgery for colorectal metastases. Cancer Res. 1991;51:6323–6327
  24. Shafir M, Shapiro R, Sung M, Warner R, Sicular A, Klipfel A. Cryoablation of unresectable malignant liver tumors. Am J Surg. 1996;171:27–31
  25. Kuramoto S. Hepatic cryosurgery for unresectable tumors. In: Presented at the American College of Cryosurgery. Venezuela. 1989;
  26. Zoras OJ, Peacock JL, Xynos E, Vassilakis SJ. The cryoablation for treatment of unresectable colorectal hepatic metastases. Int J Oncol. 1995;7:974
  27. Korpan NN. Hepatic cryosurgery for liver metastases. In: Long term follow-up. Ann Surg. 225:1997;p. 193–201
  28. Stubbs RS, Booth MW, Alwan MH. Hepatic cryotherapy followed by hepatic arterial 5FU for colorectal liver metastases. In: 25th Conference of the New Zealand Society for Oncology. Auckland, New Zealand. 1996;
  29. Stewart GJ, Preketes A, Horton M, Ross WB, Morris DL. Hepatic cryotherapy: Double-freeze cycles achieve greater hepatocellular injury in man. Cryobiology. 1995;32:215–219
  30. Cozzi PJ, Stewart GJ, Morris DL. Thrombocytopenia after hepatic cryotherapy for colorectal metastases: Correlates with hepatocellular injury. World J Surg. 1994;18:774–776
  31. Ross WB, Morris DL, Morris L, Walters A. Cardiac rhythm disturbances due to caval occlusion during hepatic cryosurgery. Cryobiology. 1994;31:501–505
  32. McLoughlin RF, Saliken JF, McKinnon G, Wiseman D, Temple W. CT of the liver after cryotherapy of hepatic metastases: Imaging findings. AJR Am Roentgenol. 1995;165:329–332
  33. Kuszyk BS, Choti MA, Urban BA, et al.  Hepatic tumors treated by cryosurgery: Normal CT appearance. AJR Am Roentgenol. 1996;166:363–368
  34. Giovannini M, Seitz JF. Ultrasound-guided percutaneous alcohol injection of small liver metastases: Results in 40 patients. Cancer. 1994;73:294–297
  35. Livraghi T, Vettori C, Lazzaroni S. Liver metastases: Results of percutaneous ethanol injection in 14 patients. Radiology. 1991;179:709–712
  36. Livraghi T, Lazzaroni S, Pellicanò S, Ravasi S, Torzilli G, Vettori C. Percutaneous ethanol injection of hepatic tumors: Single-session therapy with general anesthesia. AJR. 1993;161:1065–1069
  37. Bartolozzi C, Lencioni R. Ethanol injection for the treatment of hepatic tumours. Eur Radiol. 1996;6:682–696
  38. Rossi S, Fornari F, Buscarini L. Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma. J Intervent Radiol. 1993;88:97–103
  39. Goldberg SN, Gazelle GS, Dawson SL, Rittman WJ, Mueller PR, Rosenthal DI. Tissue ablation with radiofrequency: effect of probe size, gauge, duration, and temperature on lesion volume. Acad Radiol. 1995;2:399–404
  40. Goldberg SN, Gazelle GS, Dawson SL, Rittman WJ, Mueller PR, Rosenthal DI. Tissue ablation with radiofrequency using multiprobe arrays. Acad Radiol. 1995;2:670–674
  41. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Monti F, Solbiati L. Saline-enhnaced RF tissue ablation in the treatment of liver metastases. Radiology. 1995;197:140
  42. Goldberg SN, Gazelle GS, Halpern EF, Rittman WJ, Mueller PR, Rosenthal PI. Radiofrequency tissue ablation: importance of local temperature along the electrode tip exposure in determining lesion shape and size. Acad Radiol. 1996;3:212–218
  43. Solbiati L, Iearce T, Goldberg SN, et al.  Percutaneous US-guided radio-frequency tissue ablation of liver metastases: treatment and follow-up in 16 patients. Radiology. 1997;202:195–203
  44. McGahan JP, Schneider P, Brock JM, Tesluk H. Treatment of liver tumors by percutaneous radiofrequency electrocautery. Semin Intervent Radiol. 1993;10:143–149
  45. Borgelt BB, Gelber R, Brady LW, Griffin T, Hendrickson F. The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int J Radiat Oncol Biol Phys. 1981;7:587–591
  46. Leibel SA, Pajak TF, Massullo V, et al.  A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: result of a Radiation Therapy Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys. 1987;7:1057–1064
  47. Phillips R, Karnofsky DA, Hamilton LD, Nickson JJ. Roentgen therapy of hepatic metastases. AJR. 1954;71:826–834
  48. Prasad B, Lee MS, Henderson FR. Irradiation of hepatic metasases. Int J Radiat Oncol Biol Phys. 1977;2:129–132
  49. Russel AH, Clyde C, Wasserman TH, Turner SS, Rotman M. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys. 1993;27:117–123
  50. Leibel SA, Guse C, Order SE, et al.  Accelerated fractionation radiation therapy for liver metasases: selection of an optimal patient population for the evaluation of late hepatic injury in RTOG studies. Int J Radiat Oncol Biol Phys. 1990;18:523–528
  51. Lawrence TS, Dworzanin LM, Walker-Andrews SC, et al.  Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyurdine. Int J Radiat Oncol Biol Phys. 1991;20:555–561
  52. Lawrence TS, Ten Haken RK, Kessler ML, et al.  The use of 3D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys. 1992;23:781–788
  53. Robertson JM, Lawrence TS, Walker S, Kessler ML, Andrews JC, Ensminger WD. The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. Int J Radiat Oncol Biol Phys. 1994;30:178
  54. Nevinny HB, Flynn JP, McLaren J. Treatment of liver metastases with floxuridine and leucovorin and concomitant hepatic radiation. In: Anti-Cancer Treatment; Sixth International Congress. Paris. February 1996;p. 135
  55. Friedman M, Cassidy M, Levine M, Phillips T, Spivack S, Resser KJ. Combined modality therapy of hepatic metastasis. Cancer. 1979;44:906–913
  56. Rotman M, Kuruvilla AM, Choi K, et al.  Response of colorectal hepatic metastases to concomitant radiotherapy and intravenous infusion 5fluorouracil. Int J Radiat Oncol Biol Phys. 1986;12:2179–2187
  57. Mohiuddin M, Chen E, Ahmad N. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J Clin Oncol. 1996;14:722–728
  58. Wiley AL, Wirtanen W, Stephenson JA, Ramirez G, Demets D, Lee JW. Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. In: A randomized study. Cancer. 64:1989;p. 1783–1789
  59. Andrews JC, Walker Sc, Ackermann RT, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med. 1994;35:1637–1644
  60. Nakhgevany KB, Mobini J, Bassett JG, Miller E. Nonabsorbable radioactive material in the treatment of carcinomas by local injections. Cancer. 1988;61:931–940
  61. Tian JH, Xu B, Zhang J, Dong BW, Liang P, Wang XD. Ultrasound-guided internal radiotherapy using yttrium-90-glass microspheres for liver malignancies. J Nucl Med. 1996;37:958–963
  62. Thomas DS, Nauta RJ, Rodgers JE, et al.  Intraoperative high-dose rate interstitial irradiation of hepatic metastases from colorectal carcinoma. Cancer. 1993;71:1977–1981
  63. Collins JM. Pharmacological rationale for regional drug delivery. J Clin Oncol. 1984;2:498–504
  64. Chen GHG, Gross JF. Intra-arterial infusion of anticancer drugs: Theoretic aspects of drug delivery and review of responses. Cancer Treat Rep. 1984;64:131–140
  65. Shepard KW, Levin B, Karl RC, et al.  Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol. 1985;3:161–169
  66. Weiss GR, Garnick MB, Osteen RT, et al.  Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol. 1983;1:337–344
  67. Ramming KP, O'Toole K. The use of the implantable chemo-infusion pump in the treatment of hepatic metastases of colorectal cancer. Arch Surg. 1986;121:1400–1404
  68. Yasuda S, Noto T, Ikeda M, et al.  Hepatic arterial infusion chemotherapy using implantable reservoir in colorectal liver metastasis. Gan To Kagaku Ryoho. 1990;17:1815–1819
  69. Campbell KA, Burns RC, Sitzman JV, Lipset PA, Crochon LB, Niederhuber JE. Regional chemotherapy devices: Effect of experience and anatomy on complications. J Clin Oncol. 1993;11:822–826
  70. Hohn DC, Melnick J, Stagg R, et al.  Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol. 1985;3:98–102
  71. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. In: A randomized trial. Ann Int Med. 107:1987;p. 459–465
  72. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685–693
  73. Hohn DC, Stagg RJ, Friedman MA, et al.  A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group Trial. J Clin Oncol. 1989;7:1646–1654
  74. Martin JK, O'Connell MJ, Wieand HS, et al.  Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer: A randomized trial. Arch Surg. 1990;125:1022–1027
  75. Rougier P, Laplanche A, Huguier M, et al.  Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol. 1992;10:1112–1118
  76. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994;344:1255–1260
  77. The Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst. 1996;88:1252–1258
  78. Harmanthas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Cancer. 1996;78:1639–1645
  79. Kemeny N, Niedzwiecki D, Shurgot B, Oderman P. Prognostic variables in patients with hepatic metastases from colorectal cancer: Importance of medical assessment of liver involvement. Cancer. 1989;63:742–747
  80. Blank RJ, Tyson IB. Intrarterial 131I-macroaggregated albumin to define intrahepatic tumors, a possible method of quantitating tumor response to therapy. J Nucl Med. 1966;10:514–516
  81. Kaplan WD, Ensminger WD, Come SE, et al.  Radionuclide angiography to predict patient response to hepatic artery chemotherapy. Cancer Treat Rep. 1980;64:1217–1222
  82. Belluco C, Guillem JC, Kemeny N, et al.  p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol. 1996;14:2696–2701
  83. Ensminger D, Niederhuber JE, Dakhil S, Thrall J, Wheeler T. Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep. 1981;65:393–400
  84. Niederhuber JE, Ensminger WD, Gyves JW, Thrall J, Walker S, Cozzi E. Regional chemotherapy of colorectal cancer to the liver. Cancer. 1984;53:1336–1343
  85. Kemeny N, Seiter K, Niedzwiecky D, et al.  A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer. 1992;69:327–334
  86. Stagg RJ, Venook AP, Chase JL, et al.  Alternating hepatic intraarterial floxuridine and fluorouracil: A less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst. 1991;83:423–428
  87. Davidson BS, Izzo F, Chase JL, et al.  Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. Am J Surg. 1996;172:244–247
  88. Kemeny MM, Alava G, Oliver J. The effects on toxicity of circadian patterning of continuous hepatic artery infusion. Surgery. 1992;5:185–194
  89. Kemeny MM, Alava G, Oliver J. The effects on liver metastases of circadian patterned continuous hepatic artery infusion of FUDR. Surgery. 1994;7:219–224
  90. Hrushesky W, von Roemelling R, Lanning R, Rabatin JT. Circadian-shaped infusion of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol. 1990;8:1504–1513
  91. Kemeny N, Seiter K, Conti J, Cohen A, Bertino JR, Sigurdson E. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma: New dose schedules and survival update. Cancer. 1994;73:1134–1142
  92. Kemeny N, Conti J, Cohen A, et al.  A phase II study of hepatic arterial FUDR, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 1994;12:2288–2295
  93. Kemeny N, Conti J, Blumgart L, et al.  Hepatic arterial infusion of floxuridine (FUDR), dexamethasone (Dex), and high dose mitomycin-C (Mit C): comparable response to FUDR/leucovorin/Dex but with greater toxicity. In: Proc Am Soc Clin Oncol. 14:1995;p. 201
  94. Metzger U, Weder W, Rothlin M, Largiader F. Phase II study of intra-arterial fluorouracil and mitomycin C for liver metastases of colorectal cancer. Recent Results Cancer Res. 1991;121:198–204
  95. Kemeny N, Cohen A, Seiter K, Conti JA, Sigurdson E, Tao Y. Randomized trial of hepatic arterial FUDR, mitomycin C and BCNU versus FUDR alone: effective salvage therapy for liver metastases of colorectal cancer. J Clin Oncol. 1993;11:330–335
  96. Safi F. Continuous simultaneous intraarterial and intravenous therapy of liver metastases of colorectal carcinoma: Results of a prospective randomized trial. In: Proc Am Soc Clin Oncol. 11:1992;p. 490; (Abstr)
  97. Lorenz M, Hottenrott C, Inglis R, Kirkowa-Reimann M. Prevention of extrahepatic disease during intra-arterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment?. In: A prospective multicenter study. Gan To Kagaku Ryoho. 16:1989;p. 3662–3671
  98. Bismuth H, Adam R, Levi F, et al.  Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509–520
  99. Yasuno M, Mori T, Takahashi K. Results of the hepatic resection of liver metastases from colorectal carcinoma after continuous hepatic arterial infusion of chemotherapy: new strategy for unresectable colorectal liver metastases. In: Proc Anti-Cancer Treatment 6th International Conference. Paris. 1996;p. 137
  100. Elias D, Lasser P, Rougier Ph, Ducreux M, Bocnel C, Bolme A. Major hepatectomy after intra-arterial chemotherapy for initially unresectable liver tumors. In: Frequency, technical problems, results and indications. Ann Chir. 50:1996;p. 130–138
  101. Vauthey JN, Marsh R, Cendan JC, Chu NM, Copeland EM. Arterial therapy of hepatic colorectal metastases. Br J Surg. 1996;83:447–455
  102. Gelin LE, Lewis DH, Nilsson L. Liver blood flow in man during abdominal surgery. II The effect of hepatic artery occlusion on the blood flow through metastatic tumor nodules. Acta Hepatosplenol. 1968;15:21–24
  103. Almersjo O, Bengmark S, Rudenstram CM, Hofstrom LO, Nilsson LAV. Evaluation of hepatic dearterialization in primary and secondary cancer of the liver. Am J Surg. 1972;124:5–9
  104. Chuang VP, Wallace S. Hepatic arterial redistribution for intrarterial infusion of hepatic neoplasms. Radiology. 1980;135:295–299
  105. Koehler RE, Korobkin M, Lewis F. Arteriographic demonstration of collateral arterial supply to the liver after hepatic artery ligation. Radiology. 1975;117:49–54
  106. Dakhil S, Ensminger WD, Cho K, Niederhuber J, Doan K, Wheeler R. Improved regional selectivity of hepatic arterial BCNU with degradable microspheres. Cancer. 1982;50:631–635
  107. Murray-Lyon M, Dawson JL, Parson VA, Holmes EC, Morton DL. Treatment of secondary hepatic tumor by ligation of hepatic artery and infusion of cytotoxic drugs. Lancet. 1970;2:172–176
  108. Rump AF, Botvinik-Helling S, Theison M, et al.  Pharmacokinetics of intraarterial mitomycin C in the chemoembolization treatment of liver metastases. Gent Pharmacol. 1996;27:669–671
  109. Kennedy KA, Rockwell S, Sartorelli AC. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res. 1980;40:2356–2360
  110. Yifintsoi T, Dobbs WA, Scanlon PS, Knopp TJ, Cassingthwaigthe JB. Regional distribution of diffusible tracers and carboned microspheres in the left ventricules of isolated dog hearts. Circ Res. 1973;33:573–587
  111. Civalleri D, Fulco RA, Vannozzi M, et al.  Liver and tumor uptake and plasma pharmacokinetics of arterial cisplatin administered with and without starch microspheres in patients with liver metastases. Cancer. 1991;68:988–994
  112. Civalleri D, Rollandi GA, Simoni G, Mallarini G, Repetto M, Bonalumi U. Redistribution of arterial blood flow in metastases bearing liver after infusion of degradable starch microspheres. Acta Chir Scand. 1985;151:613–617
  113. Civalleri D, Scopinaro G, Simoni G, et al.  Starch microspheres induced arterial flow redistribution after occlusion of replaced hepatic arteries in patients with liver metastases. Cancer. 1986;58:2151–2155
  114. Civalleri D, Scopinaro G, Belletto N, et al.  Changes in vascularity of liver tumors after hepatic arterial embolization with degradable starch microspheres. Br J Surg. 1989;76:699–703
  115. Gulesserian HP, Lawton R, Condon RE. Hepatic artery ligation and cytotoxic infusion in treatment of liver metastases. Arch Surg. 1972;105:280–282
  116. Ramming KP, Sparks FC, Eiber FR, Holmes EC, Morton DL. Hepatic artery ligation and 5FU infusion for metastatic colon carcinoma and primary hepatoma. Am J Surg. 1976;132:236–240
  117. Dahl EP, Fredlund PE, Tylen U, Bengmark S. Transient hepatic dearterialization followed by regional intra-arterial 5-fluorouracil infusion as treatment for liver tumors. Ann Surg. 1981;193:82–88
  118. Patt YZ, Peters RE, Chuang VP, Wallace S, Mavligit G. Effective retreatment of patients with colorectal cancer and liver metastases. Am J Med. 1983;75:237–240
  119. Aronsen KF, Teder H, Lindberg B. Indications and therapeutic possibilities using degradable microspheres in liver malignancies. Rec Res Cancer Res. 1986;100:282–288
  120. Hunt TM, Flowerdew ADS, Birch SJ, Williams JD, Mullee MA, Taylor J. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5FU and degradable starch microspheres for colorectal liver metastases. Br J Surg. 1990;77:779–782
  121. Goldberg JA, Kerr DJ, Wilmott N, McKillop JH, McArdle CS. Regional chemotherapy for colorectal liver metastases: a phase II evaluation of targeted hepatic arterial 5FU for colorectal liver metasases. Br J Surg. 1990;77:1238–1240
  122. Taguchi T, Ogawa N, Bunke B, Nilsson B  the DSM Study Group. The use of degradable starch microspheres with intrarterial chemotherapy for the treatment of primary and secondary liver tumors-results of a phase III clinical trial. Reg Cancer Treat. 1992;4:161–165
  123. Civalleri D, Pector JC, Hakansson L, Arnaud JP, Duez N, Buyse M. Treatment of patients with unresectable liver metastases from colorectal cancer by chemo-occlusion with degradable starch microspheres. Br J Surg. 1994;81:1338–1341
  124. Martinelli DJ, Wadler S, Bakal CW, Cynamon J, Rozenblit A, Haynes H. Utility of embolization or chemoembolization as second line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer. 1994;74:1706–1712
  125. Lines AC. Percutaneous hepatic arterial chemotherapy and chemoembolization. Cancer Nursing. 1993;16:283–287
  126. Berger DH, Carrasco CH, Hohn D, Curley SA. Hepatic artery chemoembolization for primary and metastatic liver tumors: posttreatment management and complications. J Surg Oncol. 1995;60:116–121
  127. Venook AP, Stagg RJ, Lewis BJ, et al.  Chemoembolization for hepatocellular carcinoma. J Clin Oncol. 1990;8:1108–1114
  128. Simons RK, Sinanana MN, Coldwell DM. Gangrenous cholecystitis as a complication of hepatic artery embolization: case report. Surgery. 1992;112:106–110
  129. Cascinu S, Wadler S. Chemo-embolization in the treatment of liver metastases from colorectal cancer. Cancer Treat Rev. 1996;22:355–363
  130. Tanada M, Saeki T, Takashima S, Mogami H, Hyoudon I, Sinno K. Intrahepatic arterial infusion chemotherapy for the colon cancer patients with liver metastases: a comparison of arterial embolization chemotherapy versus continuous arterial infusion chemotherapy. Gan To Kagaku Ryoho. 1996;23:1440–1442

PII: S0305-7372(98)90067-6

Cancer Treatment Reviews
Volume 24, Issue 1 , Pages 3-14 , February 1998

Article Tools